Lifestyle Interventions to Prevent cOgnitive Deficits in Subjects With Depressive Symptoms: From mEchanisms to Clinical pRactice

Lifestyle Interventions to Prevent cOgnitive Deficits in Subjects With Depressive Symptoms: From mEchanisms to Clinical pRactice (POWER)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07462013

Acronym

POWER

Enrollment

120

Registered

2026-03-10

Start date

2025-10-01

Completion date

2028-09-01

Last updated

2026-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder (MDD)

Brief summary

POWER project is a randomized, controlled, non-profit study with the primary objective of testing the effectiveness of non-pharmacological interventions-such as physical activity, cognitive training, and dietary supplementation-in reducing depressive symptoms and preventing or delaying cognitive impairments that frequently co-occur in individuals with Major Depressive Disorder (MDD).

Interventions

DIETARY_SUPPLEMENTSoybean oil (Standard treatment)

3g/day of Soybean Oil

DIETARY_SUPPLEMENTEicosapentaenoic acid (omega-3 fatty acid)

3 grams/day

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Intervention model description

Participants will be randomly assigned to one of two groups: 1) soybean oil placebo, 2) omega-3 PUFA supplementation (3g/day of eicosapentaenoic acid (EPA)).

Eligibility

Sex/Gender

ALL

Age

50 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Aged 50-80 years old * Major Depressive Disorder * Absence or mild cognitive impairment

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Depressive Symptoms	Weeks 0, 4, 8, 12, 16, 24	The 17-item version (HAMD-17) is used to quantify the severity of depression. A score of ≥18 shows a significant depression level.
Executive Functioning	Weeks 0, 4, 12, 24	The Trail Making Test (TMT) evaluates cognitive impairment by measuring the time (in seconds) to complete tasks. Higher scores indicate slower, more impaired performance.
General Cognitive Ability and Memory & Attention	Weeks 0, 4, 12, 24	The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) uses age-corrected index scores (Mean=100, SD=15) to identify cognitive impairment. Cutoff points for identifying impairment are set at 1 or 1.5 standard deviations (SD) below the mean.
Processing Speed	Weeks 0, 4, 12, 24	Commonly used cut-off points for identifying cognitive impairment using the Digit Symbol Substitution Test (DSST) often fall within the range of lower than or equal to 25-35 points.

Secondary

Measure	Time frame	Description
Gut microbiome composition	Weeks 0 and 24	Gut microbiota composition is primarily measured by analyzing microbial DNA extracted from fecal (stool) samples.
Fatty Acids Profiles in Blood	Weeks 0 and 24	Fatty acid (FA) profiles in blood (red blood cells) are primarily measured using gas chromatography (GC).

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 18, 2026